News|Articles|September 20, 2024
Reliable and Objective Antibody Analysis with the New Agilent ProteoAnalyzer System
Author(s)Agilent Technologies
This technical overview compares the characterization of NISTmAb using the ProteoAnalyzer with published NIST data obtained via traditional single capillary CE-SDS technology. The results show strong correlation with the reference data, confirming that the ProteoAnalyzer is a reliable tool for analytical workflows.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
2
Everything to Know About Cell and Gene Therapy in 2025
3
Biotech Equipment Market to Approach $144B by 2030: Implications for Pharma R&D
4
CGT Innovations: The Three-Pronged Strategy for Industry Growth (Part 2)
5
